Medicinova MN-166-ALS-2301, COMBAT-ALS: Phase 2b/3, placebo-controlled trial of MN-166/Ibudilast in participants with Amylotrophic Lateral Sclerosis (ALS)

C
Cynthia Bodkin, MD

Primary Investigator

Recruiting
18 years - 80 years
All
Phase 2/3
10 participants needed
2 Locations

Brief description of study

Who is Eligible
  • Ages 18-80
  • Diagnosis of ALS with symptoms starting less than 18 months ago
  • Able to swallow medication capsules
  • No history of cancer within last 5 years
  • No use of tracheostomy or almost continuous ventilator support

What is Invovled
  • In-person appointments at the IUH Neuroscience Center
  • Participants will take Ibudilast capsules twice daily for approximately 18 months of participation.  Some telephone appointments available.

Compensation
  • Compensation available via payment card for each completed appointment

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Amylotrophic Lateral Sclerosis,ALS
  • Age: 18 years - 80 years
  • Gender: All


Updated on 01 Aug 2024. Study ID: 2001659563

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team